TL;DR
Three top executives sell shares after stock surges over 1,000% in past year.
July 16, 2025
Monopar Therapeutics Inc. (NASDAQ: MNPR) witnessed significant insider selling activity on July 14, 2025, as three key executives disposed of $1.7 million worth of shares following the biotech company’s remarkable 1,057% stock surge over the past year.
The coordinated sales come as the $249 million market cap company trades near historic highs at approximately $41 per share.
Sale Details
The selling activity involved the company’s top leadership executing simultaneous transactions. All three executives conducted their sales at similar price ranges between $40.00 and $40.25 per share, suggesting coordinated timing to capitalize on current market valuations.
Notably, each executive also exercised stock options on the same day to acquire shares at significantly lower prices:
- Robinson exercised options to acquire 16,800 shares at $0.005 per share for a total cost of just $84.
- Starr similarly acquired 16,800 shares for $84 total
- Tsuchimoto exercised options for 8,904 shares at minimal cost, acquiring an additional 4,200 shares granted in April 2016 and 4,704 shares granted in February 2017.
Market Context
The insider selling follows an extraordinary run for Monopar’s stock, which has delivered over 1,000% returns to shareholders in the past twelve months.
The dramatic appreciation reflects growing investor confidence in the company’s late-stage drug pipeline, particularly its Wilson disease treatment ALXN1840.
The timing of the sales appears strategic, with executives capitalizing on peak valuations while the stock trades near all-time highs.
Current analyst price targets range from $40.08 to $76.00, suggesting potential for continued upside despite the recent insider activity.
Strategic Developments
Monopar has achieved several significant milestones that contributed to its stock appreciation. The company recently gained inclusion in both the Russell 3000 and Russell 2000 indexes, providing enhanced institutional visibility and potential buying pressure.
The biotech’s primary value driver remains ALXN1840, a Wilson disease treatment acquired from AstraZeneca’s subsidiary.
Despite AstraZeneca previously halting development due to Phase II concerns, Monopar’s Phase III trials demonstrated promising results, showing a threefold increase in copper mobilization compared to standard care.
Analyst Coverage
Chardan Capital Markets recently initiated coverage with a Buy rating and $60 price target, highlighting the potential of both the Wilson disease treatment and the company’s radiopharmaceutical pipeline.
The firm noted ALXN1840’s significant efficacy in Phase III trials and Monopar’s plans to seek FDA approval in early 2026.
Conclusion
The coordinated insider selling represents typical profit-taking behavior following exceptional stock performance rather than concerns about company fundamentals.
With ALXN1840 approaching potential FDA approval and strong analyst support, Monopar appears well-positioned despite the recent executive share disposals.
The company continues fundraising efforts to support clinical and regulatory activities as it advances toward commercialization.